<PAGE>


                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

                                   (Mark One)
 [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
                                    OF 1934

                  For the quarterly period ended JUNE 30, 2003

       [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
      For the transition period from _________________ to _________________

                         Commission file number 0-29989

                     GLOBAL MEDICAL PRODUCTS HOLDINGS, INC.
        (Exact name of small business issuer as specified in its charter)

                                     Nevada
         (State or other jurisdiction of incorporation or organization)

                                   86-0889096
                        (IRS Employer Identification No.)

                        23282 Mill Creek Drive, Ste. 225
                             Laguna Hills, CA 92653
                    (Address of principal executive offices)

                                 (949) 305-7105
                           (Issuer's telephone number)

                                 Not Applicable
              (Former name, former address and former fiscal year,
                         if changed since last report)

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

         Check whether the registrant filed all documents and reports required
to be filed by Section l2, 13 or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court. Yes [ ] No [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS

         State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date: 86,042,035

    Transitional Small Business Disclosure Format (Check one): Yes [ ] No [X]

                                       1
<PAGE>


                     GLOBAL MEDICAL PRODUCTS HOLDINGS, INC.
                                AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)

                                   Form 10-QSB

                                TABLE OF CONTENTS

                                                                      Page
                                                                      Number
Part I    Financial Information

          Item 1     Financial Statements                                  3

                     Consolidated Balance Sheet as of
                     June 30, 2003 (Unaudited)                             3

                     Consolidated Statements of Operations
                     for the three months and nine months
                     ended June 30, 2003 and 2002 (Unaudited)              4

                     Consolidated Statements of Cash Flows
                     for the nine months ended June 30,
                     2003 and 2002 (Unaudited)                             5

                     Notes to Consolidated Financial
                     Statements                                            6

          Item 2     Management's Discussion and Analysis
                     or Plan of Operation                                  7

          Item 3     Controls and Procedures                               10

Part II   Other Information                                                10

          Item 1     Legal Proceedings                                     10
          Item 2     Changes in Securities and Use of
                     Proceeds                                              10
          Item 3     Defaults upon Senior Securities                       10
          Item 4     Submission of Matters to a Vote of
                     Security Holders                                      10
          Item 5     Other Information                                     10
          Item 6     Exhibits and Reports on Form 8-K                      10

Signatures                                                                 11

Certifications                                                             12

Exhibit 15 Independent Auditors Report                                     14


                                       2
<PAGE>

PART I-- FINANCIAL INFORMATION

Item 1. Financial Statements.





             GLOBAL MEDICAL PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                      CONDENSED CONSOLIDATED BALANCE SHEET
                               AS OF JUNE 30, 2003
                               -------------------
                                   (UNAUDITED)

                                     ASSETS
                                     ------

CURRENT ASSETS
   Cash                                                             $        16
   Accounts Receivable                                                  103,370
                                                                    ------------
     Total Current Assets                                               103,386
                                                                    ------------

TOTAL ASSETS                                                        $   103,386
                                                                    ============

                    LIABILITIES AND STOCKHOLDERS' DEFICIENCY
                    ----------------------------------------

CURRENT LIABILITIES
   Accounts payable and accrued expenses                            $   271,646
   Notes payable                                                         83,774
      Deferred Revenues                                                  58,094
                                                                    ------------
     Total Current Liabilities                                          413,514
                                                                    ------------

STOCKHOLDERS' DEFICIENCY
   Preferred stock, $.001 par value, 50,000,000 shares authorized,
    31,912,467 shares issued and outstanding                              3,630
   Common stock, $.001 par value, 400,000,000 shares authorized,
    62,042,035 shares issued and outstanding                             62,042
   Additional paid-in capital                                         9,480,063
   Accumulated deficit - April 1, 2003                               (7,552,250)
   Loss for the period                                                  (68,613)
   Stocks held in trust                                              (1,658,000)
   Deferred compensation expense                                       (577,000)
                                                                    ------------
     Total Stockholders' Deficiency                                    (310,128)
                                                                    ------------

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY                      $   103,386
                                                                    ============

           See accompanying notes and accountants' report to condensed
                       consolidated financial statements.

                                       3
<PAGE>

<TABLE>
                                               GLOBAL MEDICAL PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES
                                                             (A DEVELOPMENT STAGE COMPANY)
                                                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                                   -----------------------------------------------
                                                                     (UNAUDITED)
<CAPTION>
                                                                                                                    For the Period
                                                                                                                         from
                                                                                                                      June 2, 2000
                                             For the Three     For the Three     For the Six       For the Six       (Inception) to
                                             Months Ended      Months Ended      Months Ended      Months Ended      June 30, 2003
                                             June 30, 2003     June 30, 2002     June 30, 2003     June 30, 2002     (As Restated)
                                             -------------     -------------     -------------     -------------     -------------
<S>                                          <C>               <C>               <C>               <C>               <C>
REVENUES                                     $          0      $      3,812      $     49,776      $      3,812      $     53,588
                                             -------------     -------------     -------------     -------------     -------------

OPERATING EXPENSES
 Professional fees                                 22,400           275,337           397,111           713,489         6,436,882
 Contract labor                                    22,069                --            41,651                --            41,651
 Other general and administrative                  24,144            71,362            32,314           191,154           177,544
 Impairment expense                                    --                --                --                --            97,901
                                             -------------     -------------     -------------     -------------     -------------
     Total Operating Expenses                      68,613           346,699           471,076           904,643         6,868,560
                                             -------------     -------------     -------------     -------------     -------------

LOSS FROM OPERATIONS                              (68,613)         (342,887)         (421,300)         (900,831)       (6,814,972)
                                             -------------     -------------     -------------     -------------     -------------

Interest expense                                       --                --                --                --          (916,000)
                                             -------------     -------------     -------------     -------------     -------------

COMPREHENSIVE LOSS                           $    (68,613)     $   (342,887)     $   (421,300)     $   (900,831)     $ (7,730,972)
                                             =============     =============     =============     =============     =============

Net loss per common share - basic
 and diluted                                 $      (.001)     $      (.001)     $      (.005)     $      (.003)
                                             =============     =============     =============     =============

Weighted average number of common
 shares outstanding -  basic and diluted       35,600,000         1,205,697        35,600,000         1,201,200
                                             =============     =============     =============     =============

                                         See accompanying notes and accountants' report to
                                           condensed consolidated financial statements.
</TABLE>

                                                                4
<PAGE>
<TABLE>

                            GLOBAL MEDICAL PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES
                                         (A DEVELOPMENT STAGE COMPANY)
                                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                -----------------------------------------------
                                                  (UNAUDITED)
<CAPTION>

                                                                                              For the Period
                                                                                                   From
                                                             For The Six      For The Six      June 2, 2000
                                                             Months Ended     Months Ended    (Inception) to
                                                             June 30, 2003    June 30, 2002    June 30, 2003
                                                              ------------     ------------     ------------
<S>                                                           <C>              <C>              <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
 Net Loss                                                     $  (421,300)     $  (932,743)     $(7,730,972)
 Adjustments to reconcile net loss to net cash used in
  operating activities:
  Stock issued for services                                       247,500          315,100        6,118,454
  Issuance of common stocks as payment for finance charge              --               --          916,500
  Amortization of deferred expenses                               194,057          583,678          675,943
  Loss on impairment                                                   --               --           97,901
 Changes in operating assets and liabilities:
  Decrease in accounts receivable and employee advances          (103,370)              --         (266,085)
    Increase in:
     Accounts payable and accrued expenses                         43,099           10,871          139,471
     Other                                                             --              100           (5,625)
                                                              ------------     ------------     ------------
         Net Cash Used In Operating Activities                    (40,014)         (75,309)         (54,413)
                                                              ------------     ------------     ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
 Purchase of property and equipment                                    --               --          (31,923)
 Other assets                                                                                           500
                                                              ------------     ------------     ------------
         Net Cash Used In Investing Activities                         --               --          (31,423)
                                                              ------------     ------------     ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
 Proceeds from officer loan                                           674           94,356            2,752
 Proceeds from issuance of notes payable                           39,250           23,500           83,100
                                                              ------------     ------------     ------------
         Net Cash Provided by Financing Activities                 39,924           94,356           85,852
                                                              ------------     ------------     ------------

NET INCREASE IN CASH                                                  (90)             506               16

CASH - BEGINNING OF PERIOD                                            106              578               --
                                                              ------------     ------------     ------------

CASH - END OF PERIOD                                          $        16      $     1,084      $        16
                                                              ============     ============     ============


                               See accompanying notes and accountants' report to
                                 condensed consolidated financial statements.
</TABLE>

                                                      5
<PAGE>


NOTE 1   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
------   -----------------------------------------------------------

       The accompanying unaudited financial statements have been prepared in
       accordance with accounting principles generally accepted in the United
       States of America and the rules and regulations of the Securities and
       Exchange Commission for interim financial information. Accordingly, they
       do not include all the information necessary for a comprehensive
       presentation of financial position and results of operations.


       It is management's opinion, however that all material adjustments
       (consisting of normal recurring adjustments) have been made which are
       necessary for a fair financial statements presentation. The results for
       the interim period are not necessarily indicative of the results to be
       expected for the year.


       For further information, refer to the consolidated financial statements
       and footnotes included in the company's Form 10KSB for the year ended
       December 31, 2002.



NOTE 2   NOTE PAYABLE - RELATED PARTY
------   ----------------------------

       At June 30, 2003, the Company was indebted to a related party for
       $83,100. The loans are non-interest bearing, unsecured and payable on
       demand.



NOTE 3   SUBSEQUENT EVENTS
------   -----------------

       On July 18, 2003, the Board of Directors of the Company voted to
       terminate the services of Stonefield Josephson, Inc. as the independent
       auditor of the Company. This was initially reported on the March 31, 2003
       10-QSB quarterly report and subsequently on Form 8-K filed with the
       Securities and Exchange Commission on August 13, 2003.

       On August 1, 2003, the Company authorized the issuance of 30,000,000
       shares of common stock in the Company via a Form S-8 Registration
       Statement to directors, consultants and attorneys as compensation. As of
       the date of this report 24,000,000 shares have been issued.



NOTE 4   GOING CONCERN
------   -------------

       As reflected in the accompanying financial statements, the Company has a
       stockholders' deficiency of $7,552,250, a net loss from operation of
       $421,300 and net cash used in operations of $40,014 for the six months
       ended June 30, 2003. The ability of the Company to continue as a going
       concern is dependent on the Company's ability to raise additional funds
       and implement its business plan. The financial statements do not include
       any adjustments that might be necessary if the Company is unable to
       continue as a going concern.

                                       6
<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation.

Forward-looking Statements

In addition to the historical information contained herein, this Form 10-QSB
contains forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties, including
risks and uncertainties set forth in this Form 10-QSB that may cause actual
results to differ materially. These forward-looking statements speak only as of
the date hereof. The Company disclaims any intent or obligation to update these
forward-looking statements.


       a. Plan of Operation.

In its previous filing on Form 10-QSB for the period ending March 31, 2003, the
Company identified three goals for the next twelve months: (1) Finalize its
Chinese acquisitions; (2) Obtain adequate short and long term financing; and (3)
Implement its business plans in China and in the United States.

In order to finalize its Chinese acquisitions and implement its business plans
in China and the United States, the Company must first acquire short and long
term financing. The Company's ability to implement its business plans and
continue as a going concern are contingent upon acquiring funding both short and
long term. The Company at present is unable to satisfy its present and short
term cash requirements. Taking into account the present state of its finances,
the Company is unable to conduct any research and development. The Company at
present has no employees and does not foresee hiring any until and unless it
acquires adequate funding. What follows is first a recapitulation of the
Company's business plans related to the Chinese acquisitions, then a discussion
of the Company's efforts at obtaining funding during the last fiscal quarter.

              (1) Finalizing the Chinese Acquisitions.

Beginning on August 6, 2002, the Company embarked upon a business strategy
provided by the Company's lead strategic consultant, Bruce W. Barren. The
strategy focused on the Company acquiring established businesses in the
international medical device and products market in order to conduct business in
the Peoples Republic of China. Mr. Barren and the Company believe that by
implementing the strategy provided by Mr. Barren, the medical device and
products market in China provides the Company with three principal business
opportunities. First is the market for manufacturing medical products and
devices in China for sale in the United States and world wide; Second is the
ability to sell medical products and devices in the Peoples Republic of China;
and Third is the ability to partner with Chinese medical research facilities in
order to promote cooperative ventures with the Company's acquired medical device
and products businesses, and potentially other medical research facilities in
the United States and worldwide.

The first business acquisition the Company initiated was that of Global Glass
Source, Ltd., a Hong Kong corporation. This acquisition agreement was initiated
in August, 2002. Global Glass Source's primary business is exporting glass
products, including medical and pharmaceutical glass containers from the Peoples
Republic of China to the United States. Global Glass has a significant U.S.
customer in H & H Glass, a California business entity that brokers, sells and
distributes glass products. The acquisition is not yet complete. The Company
next acquired Shanghai Ecom International Trading Company, Inc., a Shanghai
corporation that engages in the business of distributing medical products and
devices throughout the Peoples Republic of China. This acquisition was initiated
on September 18, 2002. Importantly, Shanghai Ecom has a Chinese governmental


                                       7
<PAGE>

license to distribute medical products and devices in the Peoples Republic of
China. Shanghai Ecom has contracts for the sale and distribution of cardio
vascular products within the Shanghai province of China with B. Braun, a German
manufacturer, and the Company believes that it is negotiating with other
international medical supply companies for distribution rights in China. The
Company believes that upon completion of its acquisition of Shanghai Ecom, it
will benefit by those contracts. However, as of the date of this filing, the
Company has not completed its acquisition of Shanghai Ecom. On October 7, 2002,
the Company entered into distribution agreements with the Lin Bi Company of the
Peoples Republic of China and the Ying Kang Medical Equipment Company, also of
the Peoples Republic of China. Both companies are in the business of
distributing a wide variety of medical equipment and health care products in
China, and have governmental licenses to distribute these products in the
Fujian, Guangdong, Guangzhou City, Guanxi, Guizhou, Hunan and Jianxi provinces
within China, representing over 400,000,000 persons and over 2,000 hospitals.

On November 15, 2002, the Company acquired the rights to EZ Trac Labs' revenue,
an operating unit of Stason Pharmaceuticals, a California corporation. EZ Trac
Labs is in the business of developing "micro-spheres" which are microscopic
beads used by medical researchers to study the effects of new surgical
procedures or newly found compounds on regional blood flow rate studies. The
micro-spheres allow medical researchers to determine how blood chemistry is
affected by various surgical procedures. EZ Trac has an existing client base
including the Mayo Foundation, Genzyme, Inc., Stanford University, the United
States Army, Texas A&M, and the University of Pennsylvania, with other
established international clientele as well in Europe and Japan. The Company
hopes to increase EZ Trac's client base by and through its Chinese medical
affiliations. This transaction became effective in January 2003.

On December 12, 2002, the Company announced that it signed a worldwide
Cooperative Technical and Sales Distribution Agreement with Standard Chemical
and Pharmaceutical, Taiwan, and also added a fourth products distribution center
in the Sichuan Province of the Peoples Republic of China.

On December 27, 2002, the Company entered into a cooperative affiliation with
the Zhongshan Hospital Group, one of the largest teaching hospitals in China,
and a center for the research and treatment of cardiac illness. The Company
believes that this association will increase the Company's visibility within
China and give it increased exposure. Also, the association included setting up
a research plus a training center within Zhongshan Hospital.

All of the above Chinese transactions, with the exception of the Standard
Chemical, Zhongshan Hospital and EZ Trac Labs transactions, are awaiting the
required written legal opinion under Hong Kong and Chinese law regarding each
acquisition's compliance with the Foreign Investment Enterprises Provisions.
These legal opinions have not been given yet, and there is no guarantee that
favorable opinions will be provided, although the Company's belief is that
positive opinions will be forthcoming. Further, doing business in the Peoples
Republic of China has inherent risks, including those of transacting business in
a communist state. Foreign relations between the United States and China, while
presently stable, may have unforeseeable consequences that would materially
affect the Company's ability to carry on business there.

Aside from the foregoing discussion of the Company's Chinese business prospects,
and assuming their closure once compliance with the Foreign Investment
Enterprises Provisions is had, the Company is looking forward to leveraging its
Chinese manufacturing and distribution acquisitions to other United States
medical companies with the desire to do business in China and to access its
large population base. The Company developed a marketing approach to exploit its
Chinese acquisitions to U.S. medical products businesses, and hired Brent
Gullick, a medical industry consultant to direct marketing efforts in this area
when all prerequisites have been satisfied.

                                       8
<PAGE>

              (2) Implementation of the Chinese business plans.

At present, the Company is satisfied that it has met all legal requirements
respecting the acquisition of the various Chinese business entities discussed
above, with the exception of Chinese legal opinion regarding the Company's
compliance with the Foreign Investment Enterprises Provisions. Once acquired,
and assuming that the Company can acquire adequate funding, the business plan
will be implemented.


              (3) Obtaining Short and Long Term Financing.

Since its last quarterly report on Form 10-QSB for the period ending March 31,
2003, the Company has been actively engaged in acquiring short and long term
financing.

On July 25, 2003 the Company, by and through efforts of lead consultant Bruce
Barren, signed a confidential letter of intent with an Alabama corporation that
presently owns business real property located between Birmingham, Alabama and
Atlanta, Georgia. The fair market value of the real property is $8,125,000.
There is an outstanding note on the property of $1,200,000 to $1,900,000
dependent on negotiation with current lien holders. The Company is negotiating
to acquire the property in exchange for a payment of preferred shares of the
Company provided by existing preferred shareholders. Negotiations regarding the
Company's acquisition of the real property are ongoing as of the date of this
filing.

Should the Company acquire the real property, it has applied for a funding
package worth $3 million dollars with a respected venture capital group. The
Company's application is contingent upon its finalizing the real property
purchase in Alabama. Further, the prospective funding entity has yet to conduct
full due diligence on the Company's proposal. Should the Company complete the
real estate transaction in Alabama and pass due diligence with the funding
entity in order to obtain the funding, then the Company believes that it can
effectively move forward with finalizing its Chinese acquisitions and implement
its business plans.

If the financing package is concluded the use of proceeds will be as follows:

       o      $1,500,000 to eliminate existing liens on property
       o      $400,000 which represents first two payments to Shanghai Ecom
       o      $175,000 to satisfy a December 31, 2003 note due on EZ Trac Labs
       o      $150,000 as part of the antibacterial licensing agreement
       o      Balance to be used as working capital and the elimination of the
              amounts owed under Current Liabilites The net results from certain
              payments would result in the recapture of approximately 18,000,000
              shares of common stock that have been prior issued.

              (4) Additional Product Licensing

The Company is currently in final negotiations to conclude a technical and
marketing licensing agreement in North America which would complement the
Company's existing licenses in the solution for antibacterial environments.

                                       9
<PAGE>

Item 3. Controls and Procedures.

(a) Evaluation of disclosure controls and procedures.

The Company maintains controls and procedures designed to ensure that
information required to be disclosed in the reports that the Company files or
submits under the Securities Exchange Act of 1934 is recorded, processed,
summarized and reported within the time periods specified in the rules and forms
of the Securities and Exchange Commission. Based upon the evaluation of those
controls and procedures performed within 90 days of the filing date of this
report, the chief executive officer and the chief financial officer of the
Company concluded that the Company's disclosure controls and procedures were
adequate.

(b) Changes in internal controls.

The Company made no significant changes in its internal controls or in other
factors that could significantly affect these controls subsequent to the date of
the evaluation of those controls by the chief executive officer and chief
financial officer.

PART II-- OTHER INFORMATION

Item 1. Legal Proceedings.

Randall Goulding, The Goulding Trust v. Global Medical Products Holdings, Inc.
(erroneously sued as "37Point9"). This action was filed originally in October,
2002 in the Circuit Court of Cook County, Illinois. In November, 2002, the
Company removed the case to the United States District Court for the Northern
District of Illinois, Eastern Division, bearing case number 02L8243. Plaintiffs'
causes of action alleged breach of contract. On July 15, 2003, a settlement
conference was held in Chicago in front of the honorable Magistrate Judge Sidney
L. Schenkier. The parties reached a settlement agreement and the action was
dismissed with prejudice. A first payment of $22,500 has been made against the
$15,000 owed with the balance to be applied against the second and final payment
due November 2003.

Magna IV, Charles Kallmann v. Global Medical Products Holdings, Inc. Case No.
GIC 792721; Superior Court for the State of California, County of San Diego.
Plaintiffs' alleged breach of contract, misappropriation of trade secrets. On
May 5, 2003, the Company and the plaintiffs entered into a settlement agreement
disposing of the action with prejudice.

 Item 2. Changes in Securities.

No rights of the holders of any class of registered securities have been
materially modified, limited or qualified by the issuance or modification of any
other class of securities. The Company has not sold unregistered securities
during this reporting period.

Item 3. Defaults Upon Senior Securities

The Company has suffered no material default in the payment of principal,
interest, a sinking or purchase fund installment, or any other material default
within 30 days of the filing of this statement, with respect to any indebtedness
exceeding 5 percent of the total assets of the Company.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information.

None.

Item 6. Exhibits and Reports on Form 8-K.

On April 2, 2003 the Company reported dismissing its independent auditor,
Weinberg & Co.

On July 18, 2003, the Company reported dismissing the independent auditor,
Stonefield Josephson, Inc.

                                       10
<PAGE>



SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


GLOBAL MEDICAL PRODUCTS HOLDINGS, INC.
(Registrant)

 August 19, 2003


/s/ DOUGLAS P. BROWN
--------------------
DOUGLAS P. BROWN, PRESIDENT





                                       11
<PAGE>

CERTIFICATIONS

I, Douglas P. Brown, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Global Medical
Products Holdings, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: August 19, 2003

/s/ Douglas P. Brown
--------------------
President


                                       12
<PAGE>


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Quarterly Report of Global Medical Products
Holdings, Inc. (the "Company") on Form 10-QSB for the period ended June 30, 2003
as filed with the Securities and Exchange Commission on the date hereof (the
"Report"), the undersigned, in the capacities and on the dates indicated below,
hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

         1. The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         2. The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operation of the
Company.

Date: August 19, 2003                   By: /S/ Douglas P. Brown
                                            -----------------------------
                                            Douglas P. Brown
                                            President, Director and
                                            Acting Chief Financial Officer


                                       13